Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Transplant Toxicities

Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT

Bone Marrow Transplantation volume 52, pages 592–599 (2017)Cite this article

Subjects

Abstract

Gemtuzumab ozogamicin (GO) may increase the risk of sinusoidal obstruction syndrome (SOS) when used prior to allogeneic stem cell transplantation (HSCT). We assessed SOS incidence and outcomes after HSCT of 146 adults, with a median age of 50 years, previously receiving GO. SOS prophylaxis was used in 69 patients (heparin n=57, ursodeoxycholic acid n=8, defibrotide n=4). Cumulative incidence (CI) of SOS was 8% (n=11), with death in 3 patients. Median interval between last GO dose and HSCT was 130 days. Overall survival (OS) and SOS incidence did not differ for patients receiving GO ⩽3.5 months before HSCT and the others. CI of acute and chronic GVHD was 31% and 25%, respectively. Probability of OS and leukemia-free survival (LFS) at 5 years was 40% and 37%, respectively. Relapse incidence and non-relapse mortality were 42% and 21%, respectively. In multivariate analysis, active disease at HSCT was associated with relapse and worse LFS and OS (P<0.03). Liver abnormalities before HSCT correlated with worse OS (P<0.03). Use of low-dose GO prior to HSCT is associated with an acceptable SOS incidence. Prospective studies investigating the role and the utility of SOS prophylaxis are warranted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16: 157–168.

    Article  PubMed  Google Scholar 

  2. Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR . Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999; 24: 891–895.

    Article  CAS  PubMed  Google Scholar 

  3. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for the treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13: 47–58.

    Article  CAS  PubMed  Google Scholar 

  4. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104: 1442–1452.

    Article  CAS  PubMed  Google Scholar 

  5. Wadleigh M, Richardson PG, Zahrieh D, Lee S, Cutler C, Ho V et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578–1582.

    Article  CAS  PubMed  Google Scholar 

  6. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121: 4854–4860.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Burnett AK, Hills RK, Milligan D, Kieldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369–377.

    Article  CAS  PubMed  Google Scholar 

  8. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30: 3924–3931.

    Article  CAS  PubMed  Google Scholar 

  9. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508–1516.

    Article  CAS  PubMed  Google Scholar 

  10. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukaemia: determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood 2010; 116: 354–365.

    Article  CAS  PubMed  Google Scholar 

  11. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A longterm clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  12. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS: 29 May 2009.

  14. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the ALFA group. Leukemia 2007; 21: 66–71.

    Article  CAS  PubMed  Google Scholar 

  15. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB . Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5: 306–315.

    Article  CAS  PubMed  Google Scholar 

  16. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007; 31: 599–604.

    Article  CAS  PubMed  Google Scholar 

  17. Kumar S, DeLeve LD, Kamath PS, Tefferi A . Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589–598.

    Article  PubMed  Google Scholar 

  18. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  19. Fine JP, Gray R . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  20. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  PubMed  Google Scholar 

  21. Carreras E, Díaz-Beyá M, Rosiñol L, Martínez C, Fernández-Avilés F, Rovira M . The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011; 17: 1713–1720.

    Article  PubMed  Google Scholar 

  22. Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socié G et al. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Bone Marrow Transplant 2014; 49: 628–633.

    Article  CAS  PubMed  Google Scholar 

  23. Mohty M, Bay J, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin–based reduced-intensity preparative regimen. Blood 2003; 102: 470–476.

    Article  CAS  PubMed  Google Scholar 

  24. Chevallier P, Prebet T, Turlure P, Hunault M, Vigoroux S, Harousseau JL et al. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45: 165–170.

    Article  CAS  PubMed  Google Scholar 

  25. Attal BM, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834–2840.

    CAS  PubMed  Google Scholar 

  26. Marsa-Vila N, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Hematol 1991; 47: 346–354.

    Article  CAS  Google Scholar 

  27. Dignan F, Gujral D, Ethell M, Evans S, Treleaven J, Morgan G et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from vno-occlusive disease. Bone Marrow Transplant 2007; 40: 79–82.

    Article  CAS  PubMed  Google Scholar 

  28. Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347–354.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Audrey Mailhol and Emmanuelle Polge for helping with data collection.

Author contributions

GB and MM designed the study. GB collected the data from the database of the ALWP of the EBMT (chaired by MM and AN). AC, RF, JEC, DB, MM, AR, NC, JMR, MS, JS, PAvdB, AB and GS were the principal investigators of the 11 highest recruiting centers of the study. ML, GB, MM and AN analyzed and interpreted the data. GB, MM and AN wrote or revised the manuscript, and all authors reviewed its final version.

Author information

Author notes

  1. A Nagler and M Mohty: These authors contributed equally to this work.

Authors and Affiliations

  1. Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France

    G Battipaglia, M Labopin, A Ruggeri & M Mohty

  2. Hematology Department, Federico II University, Naples, Italy

    G Battipaglia

  3. Hospital Saint-Antoine, Paris University UPMC, Paris, France

    M Labopin & M Mohty

  4. Hematology Department, Azienda Ospedaliero Universitaria S Maria della Misericordia di Udine, Udine, Italy

    A Candoni & R Fanin

  5. Hematology Department, Institut Paoli-Calmettes, Marseille, France

    J El Cheikh & D Blaise

  6. Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

    M Michallet

  7. Hematology Department, Centre Becquerel, Rouen, France

    N Contentin

  8. Department of Hematology, ICO Badalona-Germans Trias i Pujol Hospital, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain

    J M Ribera

  9. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

    M Stadler

  10. Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    J Sierra

  11. Hematology Department, Leiden University Medical Center, The Netherlands

    P A von dem Borne

  12. The Christie Clinic, Manchester, UK

    A Bloor

  13. Haematology Department, Hopital Saint-Louis, Paris, France

    G Socié

  14. Acute Leukemia Working Party of EBMT, Paris, France

    A Nagler & M Mohty

  15. Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel

    A Nagler

Authors
  1. G Battipaglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Candoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Fanin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J El Cheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Ruggeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Contentin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J M Ribera
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Stadler
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P A von dem Borne
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Bloor
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Battipaglia.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

List of participating centers

List of participating centers

The following transplant centers (in alphabetical order of the country) contributed cases for the study: Department of Clinical Hematology, Universitair Ziekenhuis Brussel, Brussels, Belgium; Hématologie CHU Amiens, France, Institut Paoli Calmettes, Marseille, France; Hopital Saint Louis, Paris, France; Hopital Claude Huriez, Lille, France; Hopital A Michallon, Pole Cancérologie, Grenoble, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Hopital Saint Antoine, Paris, France; Centre Becquerel, Rouen, France; Hopital Saint Louis, Paris, France; Hannover Medical University, Hannover, Germany; Azienda Ospedaliero Universitaria S Maria della Misericordia di Udine, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; ICO-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Reina Sofia, Cordoba, Spain; The Christie Clinic, Manchester, United Kingdom.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Battipaglia, G., Labopin, M., Candoni, A. et al. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 52, 592–599 (2017). https://doi.org/10.1038/bmt.2016.302

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.302

This article is cited by

Search

Advanced search

Quick links